RRMS
MCID: RLP002
MIFTS: 49

Relapsing-Remitting Multiple Sclerosis (RRMS) malady

Summaries for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
8Disease Ontology, 32MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
Disease Ontology:8 A multiple sclerosis that is characterized by relapse (attacks of symptom flare-ups) followed by remission (periods of recovery). symptoms may vary from mild to severe, and relapses and remissions may last for days or months. more than 80 percent of people who have ms begin with relapsing-remitting cycles.

MalaCards: Relapsing-Remitting Multiple Sclerosis, also known as multiple sclerosis, relapsing-remitting, is related to multiple sclerosis and optic neuritis. An important gene associated with Relapsing-Remitting Multiple Sclerosis is MIR17 (microRNA 17), and among its related pathways are Classical antibody-mediated complement activation and Immune response Fc epsilon RI pathway. The drugs glatiramer acetate and glatiramer and the compounds quinolinic acid and pge2 have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and b cells.

Aliases & Classifications for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
8Disease Ontology, 44Novoseek, 60UMLS, 34MeSH, 56SNOMED-CT
See all sources

Aliases & Descriptions:

relapsing-remitting multiple sclerosis 8
multiple sclerosis, relapsing-remitting 60
multiple sclerosis relapsing-remitting 44
relapsing-remitting ms 8
rrms 8


External Ids:

Disease Ontology8 DOID:2378
SNOMED-CT56 426373005
MeSH34 D020529

Related Diseases for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Relapsing-Remitting Multiple Sclerosis via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 64)
idRelated DiseaseScoreTop Affiliating Genes
1multiple sclerosis32.4MMP19, KLRK1, CCR7, IFNB1, FOXP3, HLA-G
2optic neuritis30.7IFNB1
3encephalomyelitis30.4CCR7, IFNB1, NTF3, IL23A
4pneumonia30.4SAA4, AOC3
5progressive relapsing multiple sclerosis10.9
6cerebritis10.6
7cervicitis10.6
8secondary progressive multiple sclerosis10.5
9neuritis10.5
10neuromyelitis optica10.4
11primary progressive multiple sclerosis10.4
12thyroiditis10.4
13autoimmune thyroiditis10.3
14lateral sclerosis10.3
15polyarteritis nodosa10.3
16neuronitis10.3
17acute disseminated encephalomyelitis10.3
18progressive multifocal leukoencephalopathy10.3
19brain disease10.3
20neutropenia10.3
21panniculitis10.3
22retinitis10.3
23thrombocytopenia10.3
24sarcoma10.0
25hepatitis10.0IFNB1
26acute leukemia10.0HLA-G
27hepatitis c10.0IFNB1
28dermatitis10.0FOXP3, NTF3, CXCL11
29herpes simplex10.0NTF3, IFNB1
30ovarian cancer10.0HLA-G, IFNB1, CCR7
31breast cancer10.0CCR7, IFNB1, HLA-G
32inflammatory bowel disease10.0FOXP3
33myeloma10.0HLA-G, KLRK1
34osteosarcoma10.0IFNB1
35dermatomyositis10.0CCR7
36diabetes mellitus10.0AOC3, FOXP3
37colorectal cancer10.0KLRK1, CCR7, HLA-G
38adenocarcinoma10.0KLRK1, IFNB1, HLA-G, NTF3
39arthritis10.0CCR7, SAA4, FOXP3, AOC3, IL23A
40influenza10.0CCR7, IFNB1
41ischemia10.0NTF4, NTF3, HCRT, PTAFR
42hepatocellular carcinoma10.0AOC3, FOXP3, IFNB1, CCR7, KLRK1
43stomach cancer10.0PTAFR, IFNB1, CCR7, KLRK1
44cervical cancer10.0HLA-G
45psoriasis10.0CCR7, HLA-G, AOC3, IL23A, MMP19, PTAFR
46viral infectious disease10.0KLRK1, IFNB1, SAA4, HLA-G, MICB
47malignant glioma10.0PTAFR, MICB, NTF3, HLA-G, IFNB1, KLRK1
48allergic rhinitis10.0FOXP3
49hypersensitivity reaction type ii disease10.0KLRK1, CCR7, IFNB1, FOXP3, HLA-G, MICB
50lung cancer10.0NOG, HLA-G, FOXP3, SAA4, IFNB1, KLRK1

Graphical network of the top 20 diseases related to Relapsing-Remitting Multiple Sclerosis:



Diseases related to relapsing-remitting multiple sclerosis

Clinical Features for Relapsing-Remitting Multiple Sclerosis

About this section

Drugs & Therapeutics for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
5CenterWatch, 41NIH Clinical Center, 6ClinicalTrials, 60UMLS, 40NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Relapsing-Remitting Multiple Sclerosis

Drug clinical trials:

Search ClinicalTrials for Relapsing-Remitting Multiple Sclerosis

Search NIH Clinical Center for Relapsing-Remitting Multiple Sclerosis

Search CenterWatch for Relapsing-Remitting Multiple Sclerosis

Inferred drug relations via UMLS60/NDF-RT40:

Genetic Tests for Relapsing-Remitting Multiple Sclerosis

About this section

Anatomical Context for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
32MalaCards
See all sources

MalaCards organs/tissues related to Relapsing-Remitting Multiple Sclerosis:

32
T cells, Brain, B cells, Testes, Bone, Spinal cord, Thyroid, Pituitary, Endothelial, Myeloid, Lung, Cortex

Animal Models for Relapsing-Remitting Multiple Sclerosis or affiliated genes

About this section

Publications for Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
50PubMed
See all sources

Articles related to Relapsing-Remitting Multiple Sclerosis:

(show top 50)    (show all 583)
idTitleAuthorsYear
1
Social Cognitive Predictors of Physical Activity in Relapsing-Remitting Multiple Sclerosis. (24407400)
2014
2
MR imaging and cognitive correlates of relapsing-remitting multiple sclerosis patients with cerebellar symptoms. (23271221)
2013
3
Secretory phospholipase A2 activity in serum and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. (23859159)
2013
4
Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. (24321154)
2013
5
Relapsing-remitting multiple sclerosis and chronic idiopathic neutropenia: a challenging combination. (23417376)
2013
6
Perception of affective prosody in patients at an early stage of relapsing-remitting multiple sclerosis. (23126275)
2013
7
Elevated and dysregulated bone morphogenic proteins in immune cells of patients with relapsing-remitting multiple sclerosis. (24080309)
2013
8
IgM to S-nitrosylated protein is found intrathecally in relapsing-remitting multiple sclerosis. (23351705)
2013
9
Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsing-remitting multiple sclerosis. (22177943)
2012
10
Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon I^-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II). (21953022)
2012
11
The relationship between enhanced plaques with Gadovist and Magnevist contrast brain magnetic resonance imaging and the neurological deficit in the acute phase of relapsing remitting multiple sclerosis. (24250860)
2012
12
Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. (22449210)
2012
13
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. (21878455)
2012
14
Natalizumab for relapsing-remitting multiple sclerosis. (21193250)
2011
15
Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. (21790210)
2011
16
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. (22010043)
2011
17
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. (22010041)
2011
18
Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. (21135017)
2011
19
Specific T-cell proliferation to myelin peptides in relapsing-remitting multiple sclerosis. (21749576)
2011
20
Disease-modifying therapies in relapsing-remitting multiple sclerosis. (20856600)
2010
21
Working memory impairment in multiple sclerosis relapsing-remitting patients with episodic memory deficits. (20464286)
2010
22
Memory B cells from a subset of treatment-naA^ve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-I^ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. (20812237)
2010
23
Functional and structural connectivity of the motor network in pediatric and adult-onset relapsing-remitting multiple sclerosis. (20093525)
2010
24
Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated. (20635996)
2010
25
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. (20064646)
2010
26
ACP Journal Club. Oral fingolimod was more effective than placebo for relapsing-remitting multiple sclerosis. (20479024)
2010
27
Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis. (19286193)
2009
28
Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. (19556316)
2009
29
Analysis of antibody reactivity in paired cerebrospinal fluid and serum of a relapsing remitting multiple sclerosis patient. (19835487)
2009
30
Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. (19527092)
2009
31
Rituximab in relapsing-remitting multiple sclerosis. (18550883)
2008
32
Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. (18003938)
2008
33
Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. (18437041)
2008
34
Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. (18074075)
2007
35
Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. (17393066)
2007
36
Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. (17463072)
2007
37
Diffusion tensor tractography-based group mapping of the pyramidal tract in relapsing-remitting multiple sclerosis patients. (17296994)
2007
38
Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. (17613607)
2007
39
Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. (17940723)
2007
40
CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone. (17827967)
2007
41
Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. (16966541)
2006
42
The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. (15997419)
2006
43
Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy. (15920290)
2005
44
Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta]. (16498805)
2005
45
Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. (17516727)
2004
46
A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis. (12581490)
2002
47
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. (11438176)
2001
48
Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. (11297592)
2001
49
Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment? (10976637)
2000
50
Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis. (1641157)
1992

Genetic Variations for Relapsing-Remitting Multiple Sclerosis

About this section

Expression for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Relapsing-Remitting Multiple Sclerosis

Search GEO for disease gene expression data for Relapsing-Remitting Multiple Sclerosis.

Pathways for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
53Reactome, 12EMD Millipore, 29KEGG
See all sources

Compounds for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
44Novoseek, 24HMDB, 49PharmGKB, 28IUPHAR, 11DrugBank
See all sources

Compounds related to Relapsing-Remitting Multiple Sclerosis according to GeneCards/GeneDecks:

(show all 24)
idCompoundScoreTop Affiliating Genes
1quinolinic acid44 2411.7HCRT, NTF3, NTF4
2pge24410.7PTAFR, IL23A
3tarc4410.7CXCL11, IFNB1, CCR7
4dexamethasone44 49 28 1113.7IFNB1, HCRT, CXCL11, NOG
5ccl344 2811.6CCR7, IFNB1, CXCL11
6ccl444 2811.6CXCL11, IFNB1, CCR7
7histamine44 28 2412.6AOC3, NTF4, NTF3, HCRT, PTAFR
8dopamine44 28 11 2413.6IFNB1, AOC3, NTF3, HCRT, NOG
9neopterin4410.6HLA-G, SAA4, IFNB1
10phosphatidylinositol4410.6KLRK1, CCR7, NTF4, NTF3, IL23A, PTAFR
11creatinine4410.5IFNB1, SAA4, HLA-G, AOC3
12rantes4410.5CCR7, IFNB1, CXCL11, PTAFR
13matrigel4410.5MMP19, NTF3, HLA-G, CCR7
14nitric oxide44 11 2412.5FOXP3, AOC3, NTF3, HCRT, IL23A, PTAFR
15ribonucleic acid4410.5HLA-G, NTF3, HCRT, NOG
16lipid4410.5CCR7, IFNB1, SAA4, HLA-G, AOC3, HCRT
17oxygen44 2411.5AOC3, HLA-G, KLRK1
18tyrosine4410.4CCR7, IFNB1, AOC3, NTF4, NTF3, HCRT
19norepinephrine44 11 2412.4CCR7, NTF3, HCRT
20p0034410.3AOC3, HLA-G, FOXP3
21calcium44 49 11 2413.3PTAFR, KLRK1, CCR7, IFNB1, SAA4, HLA-G
22retinoic acid44 2411.3KLRK1, IFNB1, NTF4, NTF3, NOG, PTAFR
23catecholamine4410.2HCRT, NTF3, AOC3
24cholesterol44 28 11 2412.9IFNB1, SAA4, HLA-G, AOC3, HCRT

GO Terms for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
Sources:
16Gene Ontology
See all sources

Cellular components related to Relapsing-Remitting Multiple Sclerosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00557610.1NOG, MMP19, CXCL11, HCRT, IGHG3, NTF3

Biological processes related to Relapsing-Remitting Multiple Sclerosis according to GeneCards/GeneDecks:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of interleukin-12 productionGO:03273510.5IL23A, HLA-G, CCR7
2mechanoreceptor differentiationGO:04249010.5NTF3, NTF4
3negative regulation of interleukin-10 productionGO:03269310.4IL23A, FOXP3
4inflammatory responseGO:00695410.4CCR7, AOC3, CXCL11, IL23A, PTAFR
5elevation of cytosolic calcium ion concentrationGO:00720410.4CCR7, HCRT, CD52
6positive regulation of neutrophil chemotaxisGO:09002310.3IL23A, CCR7
7positive regulation of transcription from RNA polymerase II promoterGO:04594410.3NOG, IL23A, NTF3, FOXP3, IFNB1
8immune responseGO:00695510.0CCR7, IGHG3, CXCL11, PTAFR

Products for genes affiliated with Relapsing-Remitting Multiple Sclerosis

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Relapsing-Remitting Multiple Sclerosis

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
50PubMed
51QIAGEN
57SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet